Search Results
Oct 06, 2025, 08:49 ET C-Greens Highlights New Study on Struggle Women With PCOS Face
ingredients for biological processes, such as: Myo-inositol (600 mg): This helps to restore hormonal balance and
More news about: California Greens
Oct 06, 2025, 08:47 ET New Report Warns of US Water Sector Crisis. THEONI Highlights the Need for a Global Response Through Responsible Water Stewardship
1100m in the Agrafa mountain range in central Greece. The water in the spring is naturally alkaline with a pH of 8 and a perfect mineral balance of 116 mg/L CaCO₃. This smooth, enriched water is naturally produced by the Goura Spring's rock bed. All THEONI has to do is bottle the
More news about: THEONI
Oct 06, 2025, 08:42 ET THEONI Natural Mineral Water: The Most Awarded Greek Water in the World Is Expanding in the US
(pH8) and boasts an exceptionally clean taste and a smooth mouthfeel. Its mineral composition is extremely balanced, at 120mg/ liter of total solids and a hardness level of 116 mg/L CaCO₃ — again, exceptionally well balanced. This composition is a gift of nature, and THEONI safeguards
More news about: THEONI
Oct 06, 2025, 08:33 ET Pusan National University Researchers Reveal How Forest Soil Properties Influence Arsenic Mobility and Toxicity in Soil Organisms
exchange capacity (CEC), phosphorus content, organic matter, metal oxides, clay content, and total arsenic. Soil samples were spiked with arsenic at 20–100 mg/kg and aged under wet-dry cycles to simulate environmental contamination. Using the Wenzel sequential extraction method, arsenic was fractionated into
More news about: Pusan National University
Oct 06, 2025, 08:30 ET Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
concomitant antipsychotic use. Results from this analysis indicated that long-term INGREZZA treatment (at doses of 40 mg, 60 mg or 80 mg) provided early and sustained improvements in chorea severity, and concomitant use of antipsychotic medication had no apparent effect on chorea
More news about: Neurocrine Biosciences, Inc.
Oct 06, 2025, 08:00 ET Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities
levels with/without Ovarian Function Suppression (OFS). In 2021, Atossa reported an 86% response rate of Ki-67 < 10% for women on low dose (4 mg/day) endoxifen in the same pre-surgery neoadjuvant setting. Published comparators in similar settings report a 41% response rate with tamoxifen and a 78%
More news about: Atossa Therapeutics Inc
Oct 06, 2025, 06:49 ET MG COMMERCIAL debuta en BusWorld Bruselas con el lanzamiento del autobús eléctrico iEV12 y el chasis B12E
barómetro del desarrollo de la industria mundial del autobús. El debut de MG marca su compromiso reforzado con la movilidad sostenible y su visión de integrar el transporte público y privado en un ecosistema integrado. MG COMMERCIAL se posiciona como una marca especializada en autobuses
More news about: MG
Oct 06, 2025, 05:16 ET PureHealth Research Launches Premium Matcha Green Tea Capsules
to ensure purity and quality. PureHealth Research's premium Matcha supplement provides a range of benefits in a simple, 1000 mg daily serving : Naturally contains L-theanine, an amino acid that supports focus
More news about: PureHealth Research
Oct 05, 2025, 20:43 ET MG COMMERCIAL debutuje na veletrhu BusWorld Brussels uvedením plně elektrického autobusu iEV12 a podvozku B12E
měřítko vývoje světového autobusového průmyslu. Debut značky MG zde představuje posílení jejího závazku k udržitelné mobilitě a vizi propojení osobní a veřejné dopravy do jednotného, plynule fungujícího ekosystému. MG COMMERCIAL je koncipována jako samostatná značka zaměřená na
More news about: MG
Oct 05, 2025, 15:27 ET MG COMMERCIAL debutuje na BusWorld Brussels s plne elektrickým autobusom iEV12 a podvozkom B12E
MG, jedna z najuznávanejších automobilových značiek na svete, debutovala na veľtrhu BusWorld Brussels s témou „Find You More." Spoločnosť oficiálne uviedla na trh svoju novú značku úžitkových vozidiel MG COMMERCIAL.
More news about: MG
Oct 05, 2025, 14:53 ET Drug that reduces iron levels in affected brain regions has a possible disease-modifying effect in people with multiple system atrophy
phase II trial by Stamler et al., participants with probable or clinically established MSA were given either 50 mg or 75 mg of ATH434 for 52 weeks. Compared to placebo, the 50 mg and 75 mg groups saw a representative disease slowing of 48% and 30%, respectively. Additionally, there was reduced iron in
More news about: International Parkinson and Movement Disorder Society
Oct 05, 2025, 02:55 ET MG COMMERCIAL дебютирует на BusWorld Brussels выпуском полностью электрического автобуса iEV12 и шасси B12E
MG, один из самых известных автомобильных брендов в мире, дебютировал на выставке BusWorld Brussels с девизом Find You More. Компания официально запустила свой новый бренд коммерческих автомобилей MG COMMERCIAL.
More news about: MG
Oct 05, 2025, 02:51 ET MG COMMERCIAL debütiert auf der BusWorld Brüssel mit der Einführung des vollelektrischen Busses iEV12 und des Fahrgestells B12E
MG, eine der bekanntesten Automobilmarken der Welt, gab sein Debüt auf der BusWorld Brussels, unter dem Motto „Find You More". Sie hat offiziell ihre neue Nutzfahrzeugmarke MG COMMERCIAL eingeführt.
More news about: MG
Oct 05, 2025, 02:49 ET MG COMMERCIAL fait ses débuts au salon BusWorld de Bruxelles avec le lancement de l'autobus tout électrique iEV12 et du châssis B12E.
développement de l'industrie mondiale de l'autobus. Les débuts de MG marquent son engagement renforcé en faveur de la mobilité durable et sa vision de l'intégration des transports personnels et publics dans un écosystème homogène. MG COMMERCIAL se positionne comme une marque dédiée aux autobus
More news about: MG
Oct 04, 2025, 11:52 ET MG COMMERCIAL Debuts at BusWorld Brussels with Launch of All-Electric iEV12 Bus and B12E Chassis
MG, one of the world's most recognized automotive brands, made its debut at BusWorld Brussels, under the theme "Find You More." It officially launched its new commercial vehicle brand MG COMMERCIAL. The
More news about: MG
Oct 04, 2025, 06:59 ET Omega-3 Market worth $7,756.4 million by 2030- Exclusive Report by MarketsandMarkets™
mandate that all infant formula and follow-on formula available for purchase within the EU must contain a minimum of 20 mg/100 kcal (or 4.8 mg/100 kJ) and a maximum of 50 mg/100 kcal (or 128 mg/100 kJ) of DHA, which is accelerating market growth. In addition, growing consumer preference for organic and clean-label
More news about: MarketsandMarkets
Oct 03, 2025, 11:25 ET SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed
More news about: Faruqi & Faruqi, LLP
Oct 03, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed
More news about: Pomerantz LLP
Oct 03, 2025, 08:38 ET Novo Nordisk: Novo estudo com Wegovy® revela perda de gordura visceral com preservação da força muscular
para o risco de doença cardiovascular.¹ O estudo demonstrou que, ao longo de 72 semanas, pacientes tratados com semaglutida 7,2mg e 2,4mg tiveram uma redução de 31% na gordura visceral, o tipo de gordura que se acumula ao redor dos órgãos internos e é um dos principais
More news about: Novo Nordisk
Oct 02, 2025, 10:00 ET Silicon Labs Series 3 SoCs Now Available to Power the Next Era of Connectivity
MG24 and
More news about: Silicon Labs
Oct 02, 2025, 09:00 ET LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
disease (ASCVD) or high-risk diabetes, who had no history of heart attack or stroke, an LDL-C ≥ 90 mg/dL, or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 120 mg/dL, or apolipoprotein B ≥ 80 mg/dL; and treated with optimized lipid-lowering therapy. Participants were randomized to receive Repatha
More news about: Amgen
Oct 02, 2025, 09:00 ET Mitsubishi Tanabe Pharma America to Present Eight ALS Research Posters at 2025 NEALS Annual Meeting
treatment cycle. For subsequent treatment cycles, RADICAVA ORS is taken for 10 days within a 14-day period followed by a 14-day drug-free period. Each 105 mg (5mL) dose of RADICAVA ORS should be taken in the morning after overnight fasting. Patients should not eat or drink (except water) within one hour after
More news about: Mitsubishi Tanabe Pharma America
Oct 02, 2025, 08:30 ET Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States
same formulations currently provided by ACTEMRA IV. The available presentations are 80 mg/4 mL (20 mg/mL), 200 mg/10 mL (20 mg/mL), 400 mg/20 mL (20 mg/mL) in single-dose vials. "Immune-mediated conditions such as rheumatoid arthritis have profound
More news about: Celltrion
Oct 02, 2025, 08:08 ET Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775
Reduce the dose for patients with DTC, RCC, or EC and severe hepatic impairment. LENVIMA (lenvatinib) is available as 10 mg and 4 mg capsules. Please see Prescribing Information for LENVIMA (lenvatinib) at
More news about: Eisai Inc.
Oct 02, 2025, 08:00 ET Health Canada Approves AGAMREE® (vamorolone) as the First Treatment for Duchenne Muscular Dystrophy in Canada
collected from four open-label studies, including extension studies. In these trials, AGAMREE® was administered at doses ranging from 2 to 6 mg/kg/day, extending for a period of up to 48 months. Compared with current standard of care corticosteroids, this novel corticosteroid treatment exhibited
More news about: Kye Pharmaceuticals Inc.